Efgartigimod Versus Lymphoplasmapheresis as Preoperative Rapid Antibody‐Clearing Therapies for Thymectomy in Generalized Myasthenia Gravis: Effectiveness, Safety and Cost Outcomes Compared to Conventional Preparation
CNS Neuroscience & Therapeutics · 2026-06 · 32 (6)
DOI: 10.1002/cns.70993 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 19.06.2026. Verfasst von Qian Zhou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China. Hauptthemen laut MEDLINE: Myasthenia Gravis, Thymectomy, Preoperative Care, Immunosuppressive Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Aims
To compare the real‐world effectiveness, surgical and economic outcomes of preoperative rapid antibody clearance therapy (RACT: lymphoplasmapheresis (LPE), efgartigimod (EFG)) versus oral immunosuppressants (Oral IS) in generalized myasthenia gravis (gMG) patients undergoing thymectomy.
Methods
This retrospective study included 78 patients (36 Oral IS, 42 RACT: 25 LPE, 17 EFG). Primary outcome: 3‐month postoperative quantitative myasthenia gravis (QMG) score. Secondary outcomes: 1‐month postoperative exacerbation rate, 3‐ and 6‐month MG activities of daily living (MG‐ADL), 6‐month QMG, surgical outcomes (operative time, blood loss, postoperative myasthenic crisis (POMC)), perioperative costs (pre‐ and post‐reimbursement). Propensity score overlap weighting balanced covariates. Sensitivity analyses used propensity matching; multiple imputation handled missing data.
Results
After weighting, 3‐month QMG scores showed no significant difference between RACT and Oral IS groups (mean difference (MD) −0.23, 95% CI: −2.99 to 2.54, p = 0.831) nor between the EFG and LPE subgroups (MD 1.15, 95% CI: −3.97 to 6.26, p = 0.567); similar for MG‐ADL. All groups improved over time ( p < 0.001). For EFG vs. LPE, 1‐month exacerbation rate was 43.3% vs. 26.1% ( p = 0.412). No significant between‐group differences between EFG and LPE were found in 6‐month QMG/MG‐ADL scores and surgical outcomes. EFG had higher preoperative pre‐reimbursement costs (MD 14,500 CNY, p = 0.026), but no cost differences remained after insurance. Sensitivity analyses confirmed robustness of the primary findings.
Conclusion
Preoperative RACT effectively reduced QMG in gMG patients, with no significant postoperative medium‐term effectiveness and safety differences between RACT and Oral IS. Similarly, no significant differences in postoperative medium‐term effectiveness, safety, or post‐reimbursement costs were observed between EFG and LPE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China.
- Clinical Research Center for Neuroimmune and Neuromuscular Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China.
- National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China.
- Department of Thoracic Surgery, Xiangya Hospital, National Clinical Research Center for Geriatric Disorders, Central South University, Changsha, People's Republic of China.
- Department of Neurology and Immunobiology, Yale School of Medicine, New Haven, Connecticut, USA.
ORCID-Profile: Kangzhi Chen, Huan Yang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhou, Q., He, T., Cheng, Y., Chen, K., Ouyang, Y., Dong, X., Shi, G., Wen, Z., & Yang, H. (2026). Efgartigimod Versus Lymphoplasmapheresis as Preoperative Rapid Antibody‐Clearing Therapies for Thymectomy in Generalized Myasthenia Gravis: Effectiveness, Safety and Cost Outcomes Compared to Conventional Preparation. CNS Neuroscience & Therapeutics, 32(6). https://doi.org/10.1002/cns.70993
Vancouver
Zhou Q, He T, Cheng Y, Chen K, Ouyang Y, Dong X, et al. Efgartigimod Versus Lymphoplasmapheresis as Preoperative Rapid Antibody‐Clearing Therapies for Thymectomy in Generalized Myasthenia Gravis: Effectiveness, Safety and Cost Outcomes Compared to Conventional Preparation. CNS Neuroscience & Therapeutics. 2026;32(6). doi:10.1002/cns.70993
BibTeX
@article{Zhou2026,
author = {Zhou, Qian and He, Ting and Cheng, Yuanda and Chen, Kangzhi and Ouyang, Yuzhen and Dong, Xiaohua and Shi, Guanzhong and Wen, Zeyi and Yang, Huan},
title = {Efgartigimod Versus Lymphoplasmapheresis as Preoperative Rapid Antibody‐Clearing Therapies for Thymectomy in Generalized Myasthenia Gravis: Effectiveness, Safety and Cost Outcomes Compared to Conventional Preparation},
journal = {CNS Neuroscience & Therapeutics},
year = {2026},
volume = {32},
number = {6},
doi = {10.1002/cns.70993}
}
EUVIMED